Chemical Compound

Vinpocetine

Ethyl apovincaminate

Evidence TierBWADA NOT PROHIBITED

tuneTypical Dose

10–30 mg (divided into 2-3 doses)

watchEffect Window

Acute (1-2 hours) for blood flow, 4-12 weeks for cognitive baselines.

check_circleCompliance

WADA NOT PROHIBITED

Overview

Clinical Summary

Vinpocetine is a semi-synthetic derivative of vincamine studied for cerebral blood flow and neuroprotection. It is used for cognitive and vertigo-related complaints, with heterogeneous and often older clinical evidence.

Some studies suggest improvements in vertigo symptoms and certain cognitive measures, possibly through cerebral perfusion and antioxidant effects, but many trials are older and methodologically heterogeneous. Evidence for stroke recovery outcomes is mixed. Minority claims include tinnitus and visual function benefits with inconsistent support. Regulatory status and safety considerations vary, and evidence is not strong enough for reliable cognitive enhancement conclusions.

Potent PDE1 inhibitor that increases cGMP/cAMP, producing cerebral-selective vasodilation and increased brain blood flow. Secondary neuroprotection via voltage-gated sodium channel blockade.

Outcomes

What This Is Expected To Influence

Primary Outcomes

  • Modest improvements in cognitive function in patients with cerebrovascular disease or dementia
  • Increased cerebral blood flow via PDE1 inhibition

Secondary Outcomes

  • Neuroprotection against excitotoxicity via sodium channel blockade
  • Increased cerebral blood flow velocity in healthy adults (limited cognitive translation)

Safety

Contraindications and Interactions

Contraindications

  • Pregnancy (FDA warning, possible fetal harm)
  • Bleeding disorders
  • Hypotension

Side effects

  • Headache
  • GI upset
  • Facial flushing

Interactions

  • Anticoagulant additive bleeding risk
  • Antihypertensives (additive BP lowering)

Avoid if

  • Women of childbearing age (FDA developmental toxicity warning)
  • Hypotension or bleeding disorders
  • On anticoagulant therapy without medical supervision

Evidence

Study-level References

vinpocetine-SRC-001Meta-analysis of RCTs
Sourceopen_in_new

Szatmari SZ, Whitehouse PJ. "Vinpocetine for cognitive impairment and dementia." Cochrane Database Syst Rev. 2003.

Population: Older adults with cognitive impairment/dementia

Key findings: Older studies show benefit for vinpocetine in the treatment of patients with dementia or cognitive decline, though modern, methodologically rigorous trials are lacking.

Paper content

Older studies show benefit for vinpocetine in the treatment of patients with dementia or cognitive decline, though modern, methodologically rigorous trials are lacking.

vinpocetine-SRC-002Narrative review.
Sourceopen_in_new

Abu-Alghayth MH, Al-Kuraishy HM, Al-Gareeb AI, et al. Atheroprotective role of vinpocetine: an old drug with new indication. Inflammopharmacology. 2024;32(6):3669-3678. doi:10.1007/s10787-024-01529-5. PMID:39141151.

Population: General discussion of atherosclerosis, endothelial dysfunction, and vinpocetine pharmacology.

Dose protocol: Review of vinpocetine pharmacology for atherosclerosis prevention

Key findings: Vinpocetine inhibits atherosclerosis formation through PDE1 inhibition, NF-kB suppression, and antioxidant activity. Blocks monocyte adhesion and stabilizes plaques.

Notes: Narrative review based primarily on preclinical data. No direct human cardiovascular trial evidence.

Paper content

This narrative review examines evidence for vinpocetine's atheroprotective properties. The authors discuss how vinpocetine, through PDE1 inhibition, NF-kB suppression, and antioxidant activity, may block monocyte adhesion, reduce inflammatory cytokine expression, and stabilize atherosclerotic plaques. While the mechanistic rationale is detailed, the review draws primarily from preclinical models and in vitro studies. Direct clinical trial evidence for vinpocetine in human atherosclerosis prevention is lacking. The paper adds to the growing interest in repurposing vinpocetine beyond cerebral blood flow indications but does not provide definitive human efficacy data for cardiovascular endpoints.

vinpocetine-SRC-003Network meta-analysis of randomized controlled trials.
Sourceopen_in_new

Wang Y, Li M, Jiang Y, Ji Q. Comparative efficacy of neuroprotective agents for improving neurological function and prognosis in acute ischemic stroke: a network meta-analysis. Front Neurosci. 2025;18:1530987. doi:10.3389/fnins.2024.1530987. PMID:39834702.

Population: Patients with acute ischemic stroke across 42 RCTs.

Dose protocol: Network meta-analysis of 42 RCTs comparing 9 neuroprotective agents in acute ischemic stroke (12,210 participants)

Key findings: Vinpocetine was included as one of nine neuroprotective agents but did not rank as the most effective, falling behind butylphthalide and edaravone for primary neurological endpoints.

Notes: Contextualizes vinpocetine against competing neuroprotective agents in the stroke setting.

Paper content

This network meta-analysis compared the efficacy of nine neuroprotective agents (including vinpocetine) for acute ischemic stroke across 42 RCTs with 12,210 participants. Butylphthalide and edaravone generally ranked higher than vinpocetine for neurological function and functional outcomes. While vinpocetine was included in the network analysis, it did not emerge as the most effective agent for the primary endpoints. The study places vinpocetine in the broader context of neuroprotective stroke therapies and suggests it has activity but is outperformed by other options. This is useful for contextualizing vinpocetine's neuroprotective claims against the current evidence landscape.

Guides

Setup

Help